Stay updated on Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedSummary: The page now displays a funding-status notice and announces a major version upgrade to v3.2.0, replacing the previous v3.1.0.SummaryDifference3%
- Check23 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The core page content shifts to the newer release identifier; no other substantive content changes are indicated.SummaryDifference0.1%
- Check38 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2, indicating a minor patch. The removal of 'Back to Top' is a minor UI change and can be disregarded.SummaryDifference0.2%
- Check45 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check52 days agoChange DetectedThe web page has updated its facility name and location details, specifically changing the address to Washington D.C., and has added new medical topics related to Thymus Cancer and Hemic and Lymphatic Diseases, along with new drug names like pembrolizumab and epacadostat.SummaryDifference2%
- Check66 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.